Drug intelligence / Profile preview

QL-901

Development stage: Preclinical
Lead developer: Shenzhen Qinglan Biotechnology
Modality: Peptides
Administration: Transdermal

Overview

QL-901 is a peptide-based glucagon-like peptide-1 (GLP-1) receptor agonist being developed by BioQingLam for the treatment of type 2 diabetes mellitus (T2DM) and obesity. The drug is administered via a soluble microneedle patch, a transdermal delivery system that allows the peptide to bypass the gastrointestinal tract and avoid the need for traditional subcutaneous injections. This technology is intended to improve patient compliance by providing a painless and user-friendly administration route. QL-901 is currently in the IND-enabling stage of development.

Targets

GLP1R (GLP-1R)

Beyond the preview

Go deeper on QL-901.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on QL-901.

Explore the full profile